openPR Logo
Press release

Iron Deficiency Anemia Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | Pharmacosmos A/S, Nemysis Ltd, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutic

12-23-2024 06:20 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Iron Deficiency Anemia Pipeline Trends 2024: Clinical Trials,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Iron Deficiency Anemia pipeline constitutes key companies continuously working towards developing Iron Deficiency Anemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Iron Deficiency Anemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Iron Deficiency Anemia Market.

The Iron Deficiency Anemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Iron Deficiency Anemia Pipeline Report: https://www.delveinsight.com/sample-request/iron-deficiency-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Iron Deficiency Anemia treatment therapies with a considerable amount of success over the years.
• Iron Deficiency Anemia companies working in the treatment market are Pharmacosmos A/S, Nemysis Ltd, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others, are developing therapies for the Iron Deficiency Anemia treatment
• Emerging Iron Deficiency Anemia therapies in the different phases of clinical trials are- Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others are expected to have a significant impact on the Iron Deficiency Anemia market in the coming years.
• In February 2024, Anemia remains a significant global public health concern, with Southeast Asia reporting some of the highest prevalence rates. This condition particularly impacts vulnerable groups, including women and children, posing serious health risks. Iron Deficiency Anemia (IDA) is the most common form, affecting as many as 1 in 4 individuals in certain Southeast Asian countries. Symptoms like fatigue, dizziness, and headaches not only diminish quality of life but also hinder productivity.


Iron Deficiency Anemia Overview
Iron Deficiency Anemia (IDA) is a common condition characterized by a lack of sufficient iron in the body to produce adequate levels of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. It can result from inadequate dietary iron intake, blood loss (e.g., from gastrointestinal bleeding), or poor iron absorption. Symptoms of IDA include fatigue, weakness, pale skin, shortness of breath, and dizziness. Treatment typically involves iron supplementation, dietary changes to increase iron-rich food intake, and addressing underlying causes of iron deficiency. Early diagnosis and management are essential to prevent complications.

Get a Free Sample PDF Report to know more about Iron Deficiency Anemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/iron-deficiency-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Iron Deficiency Anemia Drugs Under Different Phases of Clinical Development Include:
• Ferric Derisomaltose: Pharmacosmos A/S
• Low Dose IHAT: Nemysis Ltd
• ferric citrate: Keryx Biopharmaceuticals
• iron isomaltoside 1000 (Monofer®): Pharmacosmos A/S
• Ferric carboxymaltose: Tigermed Consulting Co., Ltd
• Ferric Maltol: Shield Therapeutics
• Z-213: Zeria Pharma
• KER-047: Keros Therapeutics, Inc.
• Ferumoxytol: AMAG Pharma
• venoferrum(iron sucrose): JW Pharmaceutical
• Z-213: Zeria Pharma

Iron Deficiency Anemia Pipeline Therapeutics Assessment
• Iron Deficiency Anemia Assessment by Product Type
• Iron Deficiency Anemia By Stage and Product Type
• Iron Deficiency Anemia Assessment by Route of Administration
• Iron Deficiency Anemia By Stage and Route of Administration
• Iron Deficiency Anemia Assessment by Molecule Type
• Iron Deficiency Anemia by Stage and Molecule Type

DelveInsight's Iron Deficiency Anemia Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Iron Deficiency Anemia product details are provided in the report. Download the Iron Deficiency Anemia pipeline report to learn more about the emerging Iron Deficiency Anemia therapies at:
https://www.delveinsight.com/sample-request/iron-deficiency-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Iron Deficiency Anemia Therapeutics Market include:
Key companies developing therapies for Iron Deficiency Anemia are - Pharmacosmos AS, Sanofi SA, Johnson and Johnson, Fresenius SE & Co. KGaA, ViforPharma Ltd., Rockwell Medical, Inc, Abbvie Inc., Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc. (Covis Group S.r.l.), Daiichi Sankyo Company, Akorn Operating Company LLC, Shield Therapeutics, and others.

Iron Deficiency Anemia Pipeline Analysis:
The Iron Deficiency Anemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Iron Deficiency Anemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Iron Deficiency Anemia Treatment.
• Iron Deficiency Anemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Iron Deficiency Anemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Iron Deficiency Anemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Iron Deficiency Anemia drugs and therapies-
https://www.delveinsight.com/sample-request/iron-deficiency-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Iron Deficiency Anemia Pipeline Market Drivers
• Increasing changes in lifestyle, Increasing cases of anemia, Growth in geriatric population, are some of the important factors that are fueling the Iron Deficiency Anemia Market.

Iron Deficiency Anemia Pipeline Market Barriers
• However, Extensive usage of over-the-counter (OTC) medications, Availability of generics, Lack of robust pipeline, and other factors are creating obstacles in the Iron Deficiency Anemia Market growth.

Scope of Iron Deficiency Anemia Pipeline Drug Insight
• Coverage: Global
• Key Iron Deficiency Anemia Companies: Pharmacosmos A/S, Nemysis Ltd, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others
• Key Iron Deficiency Anemia Therapies: Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others
• Iron Deficiency Anemia Therapeutic Assessment: Iron Deficiency Anemia current marketed and Iron Deficiency Anemia emerging therapies
• Iron Deficiency Anemia Market Dynamics: Iron Deficiency Anemia market drivers and Iron Deficiency Anemia market barriers

Request for Sample PDF Report for Iron Deficiency Anemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/iron-deficiency-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Iron Deficiency Anemia Report Introduction
2. Iron Deficiency Anemia Executive Summary
3. Iron Deficiency Anemia Overview
4. Iron Deficiency Anemia- Analytical Perspective In-depth Commercial Assessment
5. Iron Deficiency Anemia Pipeline Therapeutics
6. Iron Deficiency Anemia Late Stage Products (Phase II/III)
7. Iron Deficiency Anemia Mid Stage Products (Phase II)
8. Iron Deficiency Anemia Early Stage Products (Phase I)
9. Iron Deficiency Anemia Preclinical Stage Products
10. Iron Deficiency Anemia Therapeutics Assessment
11. Iron Deficiency Anemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Iron Deficiency Anemia Key Companies
14. Iron Deficiency Anemia Key Products
15. Iron Deficiency Anemia Unmet Needs
16 . Iron Deficiency Anemia Market Drivers and Barriers
17. Iron Deficiency Anemia Future Perspectives and Conclusion
18. Iron Deficiency Anemia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Iron Deficiency Anemia Market https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Iron Deficiency Anemia Epidemiology https://www.delveinsight.com/report-store/iron-deficiency-anemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Iron Deficiency Anemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market
• Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market
• Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Iron Deficiency Anemia Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | Pharmacosmos A/S, Nemysis Ltd, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutic here

News-ID: 3795922 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Anemia

Rising Cancer And Anemia Cases Propel Growth In Chemotherapy-Induced Anemia Mark …
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Chemotherapy-Induced Anemia Market Size During the Forecast Period? The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM. DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435 This latest report researches the industry structure,
Anemia Drugs Market 2018 Grow at CAGR of 8.4% to Reach USD 34.7 Billion | By Uni …
Market Research Future Published a Prime research Report on “Global Anemia Drugs Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022 Global Anemia Drugs Market - Segments Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration;
Anemia in Chronic Kidney Disease (Renal Anemia) - Industry Analysis, Trends, and …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Anemia in Chronic Kidney Disease Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196648 Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017,
Global Anemia in Chronic Kidney Disease (Renal Anemia) Clinical Trials Market Re …
Market Research Hub's clinical trial report, Global Anemia in Chronic Kidney Disease (Renal Anemia) Clinical Trials Review, H1, 2017, provides an overview of Anemia in Chronic Kidney Disease (Renal Anemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Anemia in Chronic Kidney Disease (Renal Anemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Request